Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain

Aswini Kumar Giri, Victor J Hruby

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: Current methods for treating prolonged and neuropathic pain are inadequate and lead to toxicities that greatly diminish quality of life. Therefore, new approaches to the treatment of pain states are needed to address these problems. Areas covered: The review primarily reviews approaches that have been taken in the peer-reviewed literature of multivalent ligands that interact with both μ and δ opioid receptors as agonists, and in some cases, also with pharmacophores for antagonist ligands that interact with other receptors as antagonists to block pain. Expert opinion: Although there are a number of drugs currently on the market for the treatment of pain; none of them are 100% successful. In the authors' opinion, it is clear that new directions and modalities are needed to better address the treatment of prolonged and neuropathic pain; one drug or class clearly is not the answer for all pain therapy. Undoubtedly, there are many different phenotypes of prolonged and neuropathic pain and this should be one avenue to further develop appropriate therapies.

Original languageEnglish (US)
Pages (from-to)227-241
Number of pages15
JournalExpert Opinion on Investigational Drugs
Volume23
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Peptidomimetics
Peptide Receptors
Opioid Receptors
Neuralgia
Pain
Ligands
Therapeutics
Expert Testimony
Pharmaceutical Preparations
Quality of Life
Phenotype

Keywords

  • Agonist
  • Multifunctionality
  • Multivalency
  • Opioid
  • Pain
  • Receptors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain. / Giri, Aswini Kumar; Hruby, Victor J.

In: Expert Opinion on Investigational Drugs, Vol. 23, No. 2, 02.2014, p. 227-241.

Research output: Contribution to journalArticle

@article{7814d4f060eb4dc6a2a7ff0d22086fb8,
title = "Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain",
abstract = "Introduction: Current methods for treating prolonged and neuropathic pain are inadequate and lead to toxicities that greatly diminish quality of life. Therefore, new approaches to the treatment of pain states are needed to address these problems. Areas covered: The review primarily reviews approaches that have been taken in the peer-reviewed literature of multivalent ligands that interact with both μ and δ opioid receptors as agonists, and in some cases, also with pharmacophores for antagonist ligands that interact with other receptors as antagonists to block pain. Expert opinion: Although there are a number of drugs currently on the market for the treatment of pain; none of them are 100{\%} successful. In the authors' opinion, it is clear that new directions and modalities are needed to better address the treatment of prolonged and neuropathic pain; one drug or class clearly is not the answer for all pain therapy. Undoubtedly, there are many different phenotypes of prolonged and neuropathic pain and this should be one avenue to further develop appropriate therapies.",
keywords = "Agonist, Multifunctionality, Multivalency, Opioid, Pain, Receptors",
author = "Giri, {Aswini Kumar} and Hruby, {Victor J}",
year = "2014",
month = "2",
doi = "10.1517/13543784.2014.856879",
language = "English (US)",
volume = "23",
pages = "227--241",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain

AU - Giri, Aswini Kumar

AU - Hruby, Victor J

PY - 2014/2

Y1 - 2014/2

N2 - Introduction: Current methods for treating prolonged and neuropathic pain are inadequate and lead to toxicities that greatly diminish quality of life. Therefore, new approaches to the treatment of pain states are needed to address these problems. Areas covered: The review primarily reviews approaches that have been taken in the peer-reviewed literature of multivalent ligands that interact with both μ and δ opioid receptors as agonists, and in some cases, also with pharmacophores for antagonist ligands that interact with other receptors as antagonists to block pain. Expert opinion: Although there are a number of drugs currently on the market for the treatment of pain; none of them are 100% successful. In the authors' opinion, it is clear that new directions and modalities are needed to better address the treatment of prolonged and neuropathic pain; one drug or class clearly is not the answer for all pain therapy. Undoubtedly, there are many different phenotypes of prolonged and neuropathic pain and this should be one avenue to further develop appropriate therapies.

AB - Introduction: Current methods for treating prolonged and neuropathic pain are inadequate and lead to toxicities that greatly diminish quality of life. Therefore, new approaches to the treatment of pain states are needed to address these problems. Areas covered: The review primarily reviews approaches that have been taken in the peer-reviewed literature of multivalent ligands that interact with both μ and δ opioid receptors as agonists, and in some cases, also with pharmacophores for antagonist ligands that interact with other receptors as antagonists to block pain. Expert opinion: Although there are a number of drugs currently on the market for the treatment of pain; none of them are 100% successful. In the authors' opinion, it is clear that new directions and modalities are needed to better address the treatment of prolonged and neuropathic pain; one drug or class clearly is not the answer for all pain therapy. Undoubtedly, there are many different phenotypes of prolonged and neuropathic pain and this should be one avenue to further develop appropriate therapies.

KW - Agonist

KW - Multifunctionality

KW - Multivalency

KW - Opioid

KW - Pain

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=84892403590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892403590&partnerID=8YFLogxK

U2 - 10.1517/13543784.2014.856879

DO - 10.1517/13543784.2014.856879

M3 - Article

C2 - 24329035

AN - SCOPUS:84892403590

VL - 23

SP - 227

EP - 241

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 2

ER -